1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Aptamer Group plc

Aptamer Group plc

APTA.L
Aptamer Group plcGB flagLondon Stock Exchange
0.48
GBp
-0.02
- -
13.90MMarket Cap
Aptamer Group plc
APTA.L
(London Stock Exchange)

Recent

price

0.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2022
2023
2024
2025
FRC
0.01
0.01
0.06
0.03
- -
- -
Revenue per Share
-0.01
-0.01
-0.03
-0.11
-0.01
- -
Basic EPS, GAAP
-0.01
- -
-0.04
-0.09
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.03
-0.04
-0.03
-0.14
-0.03
-0.01
Book Value per Share
0.01
- -
0.12
- -
- -
- -
Tangible Book Value per Share
69
69
65
69
415
1,794
Basic Weighted Avg Shares
1
1
4
2
1
1
Sales/Revenue/Turnover
-54.75
-107.9
-63.83
-465.58
-363.95
-219.87
Operating Margin (%)
- -
- -
- -
3
- -
- -
Depreciation Expense
- -
-1
-2
-8
-3
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-46.11
-78.96
-51.86
-447.26
-343.95
-201.5
Profit Margin (%)
1
- -
7
- -
- -
1
Working Capital
- -
- -
1
1
1
- -
LT Debt
1
- -
8
- -
1
1
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
650.81%
55.81%
Free Cash Flow
- -
203.31%
-15.38%
Net Income, GAAP
- -
90.52%
-18.05%
Sales/Revenue/Turnover
- -
58.26%
39.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Pharma Mar, S.A. (PHM.MC)
Valneva SE (VLA.PA)
Regen BioPharma, Inc. (RGBPP)
Channel Therapeutics Corporation (CHRO)
Lineage Cell Therapeutics, Inc. (LCTX)
Alphamab Oncology (9966.HK)
Business
Aptamer Group plc develops advanced synthetic binding agents for various applications across research, diagnostics, and therapeutics globally. The company leverages its proprietary Optimer® platform to engineer next-generation affinity reagents designed to overcome limitations often associated with conventional antibodies. These Optimer binders offer superior specificity, high stability, and accelerated development timelines, providing versatile solutions to bioprocessing experts, diagnostic developers, and pharmaceutical researchers. Through its tailored services, Aptamer Group assists pharmaceutical enterprises, diagnostic firms, and academic institutions worldwide in discovering and optimizing binders for complex targets. Recent advancements include the Optimer+ platform, which delivers enhanced binding affinity and quicker development, and a growing portfolio of licensing agreements, such as royalty deals for Alzheimer's diagnostics and vaccine adjuvants. Established in 2008 and headquartered in York, United Kingdom, the company continues to expand its commercial partnerships and revenue streams, including contracts with leading global pharmaceutical companies for biomarker research and targeted therapies.